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Abstract: Nanoparticles (NPs) based on the polymer poly (lactide-co-glycolide) acid (PLGA) have
been widely studied in developing delivery systems for drugs and therapeutic biomolecules, due to
the biocompatible and biodegradable properties of the PLGA. In this work, a synthesis method for
bone morphogenetic protein (BMP-2)-loaded PLGA NPs was developed and optimized, in order to
carry out and control the release of BMP-2, based on the double-emulsion (water/oil/water, W/O/W)
solvent evaporation technique. The polymeric surfactant Pluronic F68 was used in the synthesis
procedure, as it is known to have an effect on the reduction of the size of the NPs, the enhancement of
their stability, and the protection of the encapsulated biomolecule. Spherical solid polymeric NPs
were synthesized, showing a reproducible multimodal size distribution, with diameters between
100 and 500 nm. This size range appears to allow the protein to act on the cell surface and at the
cytoplasm level. The effect of carrying BMP-2 co-adsorbed with bovine serum albumin on the NP
surface was analyzed. The colloidal properties of these systems (morphology by SEM, hydrodynamic
size, electrophoretic mobility, temporal stability, protein encapsulation, and short-term release profile)
were studied. The effect of both BMP2-loaded NPs on the proliferation, migration, and osteogenic
differentiation of mesenchymal stromal cells from human alveolar bone (ABSC) was also analyzed
in vitro.
Keywords: BMP-2; PLGA nanoparticles; Pluronic F68
1. Introduction
In the context of nanomedicine, tissue regeneration using colloidal micro- and nano-structures
having unique size and surface activity has received increasing attention over recent years. Many efforts
have been made to improve the engineering of these nano-systems in order to reach a “smart” delivery
of bioactive molecules in order to optimize their therapeutic advantages and minimize harmful side
effects [1]. With this aim, a broad spectrum of biocompatible nanocarriers has been described, showing
properties suitable for different biological and therapeutic applications [2]. Among these varied
proposals, polymeric nanosystems represent a major group in which poly lactic-co-glycolic acid (PLGA)
is one of the most widely used due to its biocompatibility, biodegradability, and low cytotoxicity,
gaining the approval from different drug agencies for human use [3,4].
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PLGA-based structures are described as micro- and nanocarriers to deliver a wide variety of active
molecules and drugs, synthetic or natural molecules with hydrophilic or hydrophobic properties, and
biomolecules from proteins to nucleic acids [5–7]. PLGA micro- and nanosystems can be set up using
different formulation techniques, with the possibility of a systemic or local distribution. These systems
can be applied not only in tissue regeneration but also in very diverse therapies: Anticancer drug
delivery, infections, inflammatory diseases, or gene therapy [3]. Despite this great potential, certain
applications, especially in protein encapsulation, are hindered by problems, such as an uncontrolled
release profile and protein denaturation [8–11].
The water-in oil-in water (W/O/W) double emulsion method is an “emulsion solvent evaporation”
technique frequently used to encapsulate hydrophilic molecules as proteins in PLGA NPs [6,12].
The appropriate choice of organic solvents, the use of polymer-surfactant blends, and the addition of
stabilizer-protective agents have proved to be key aspects for optimizing the resulting systems [9,11].
Additionally, a surface specific functionalization can be used to improve their versatility, allowing
the chemical surface immobilization of different molecules in order to confer targeting or adhesive
properties to these nanocarriers [13].
Within tissue engineering, bone regeneration has a broad range of applications, mostly in the field
of dentistry, where PLGA is suggested as a reference polymer to formulate NPs with bone-healing
uses [14]. The literature describes the delivery of bioactive molecules, normally growth factors, using
polymeric microparticles (MPs) and NPs with PLGA as the main component [13]. Among the bone
morphogenetic growth factors, BMP-2 (bone morphogenetic protein 2) has been the most frequently
cited, with many examples in which encapsulation or surface adsorption enables adequate entrapment
efficiency and diverse release patterns [15–19]. For proteins with a very short half-life, such as BMPs,
biodegradable PLGA nanosystems provide protection and optimal dosage for an adequate stimulation
of cell differentiation [20,21].
Thus, within this scenario, in the present work, we seek to optimize a nano-particulate system in
order to carry out and control the release of BMP-2 using as a starting point the synthesis procedure of
a lysozyme-loaded NP system, previously described for the encapsulation of that model protein [11].
Also, to encapsulate BMP-2, we prepared a second system in which this protein was co-adsorbed
with bovine serum albumin onto the surface of empty NPs. The size and morphology, the protein
encapsulation efficiency, the surface characteristics, and the colloidal and temporal stability were
studied to complete the physico-chemical characterization of both NP systems.
The release profile of BMP-2 indicates the potential of a PLGA nanocarrier for bone regeneration
and depends heavily on the polymer degradation by hydrolysis [22]. However, over the short
term, during which the release does not depend on this chemical degradation, proper control of
release is necessary in order to modulate other physical processes. Thus, we focused our release
experiments on the short-term using different techniques to compare the two NP samples and establish
the corresponding BMP-2 release profiles. Finally, the biological activity (cell migration, proliferation,
and osteogenic differentiation) was tested in vitro using mesenchymal stromal cells (MSCs) derived
from alveolar bone [23].
2. Materials and Methods
2.1. Nanoparticle Synthesis
2.1.1. Formulation
Poly(lactide-co-glycolide) acid (PLGA 50:50) ([C2H2O2]x[C3H4O2]y), x = 50, y = 50 (Resomer®
503H, (Evonik, Essen, Germany), 32–44 kDa was used as the polymer, and polymeric surfactant
Pluronic F68 (Poloxamer 188) (Sigma-Aldrich, St. Louis, MO, USA) as the emulsifier. Their structure,
based on a poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide), is expressed
as PEOa-PPOb-PEOa with a = 75 and b = 30. Human recombinant bone morphogenetic protein,
rhBMP-2 (Sigma-H4791), was used as therapeutic biomolecule. Water was purified in a Milli-Q
Pharmaceutics 2019, 11, 388 3 of 18
Academic Millipore system. A double-emulsion synthesis method was used following a procedure
previously described with slight modifications [11]. In this method, 100 mg of PLGA and 3 mg of
deoxycholic acid (DC) were dissolved in a tube containing 1 mL of ethyl acetate (EA) and vortexed.
In total, 40 µL of a buffered solution at pH 12.8, with or without rhBMP-2 (200 µg/mL), were added
and immediately sonicated (Branson Ultrasonics 450 Analog Sonifier) for 1 min (Duty cycle dial: 20%,
Output control dial: 4) with the tube surrounded by ice. This primary W/O emulsion was poured into
a plastic tube containing 2 mL of a buffered solution (pH 12) of F68 at 1 mg/mL, and vortexing for
30 s. Then, the tube surrounded by ice was sonicated at the maximum amplitude for the micro tip for
1 min (Output control: 7). This second W/O/W emulsion was poured into a glass containing 10 mL of
the buffered F68 solution and kept under magnetic stirring for 2 min. The organic solvent was then
rapidly extracted by evaporation under vacuum to a final volume of 8 mL. The resulting empty and
BMP-2 encapsulated NP systems were named NP and NP-BMP2, respectively. A detailed scheme of
the synthesis procedure, with a yield based on the PLGA component always higher than 85%, is shown
in Figure S1 of the Supplementary Materials.
2.1.2. Cleaning and Storage
After the organic solvent evaporation, the sample was centrifuged for 10 min at 20 ◦C at 12,000 rpm.
The supernatant was filtered using Millipore nanofilters, 0.1µm for measuring the free non-encapsulated
protein. The pellet was then resuspended in phosphate buffer (1.15 mM NaH2PO4), PB, to a final
volume of 4 mL and kept refrigerated at 4 ◦C. Under these conditions, the systems kept colloidal
stability at least for one month.
2.1.3. Protein Loading and Encapsulation Efficiency
The initial protein loading was optimized for the nanoparticle formulation, preserving the final
colloidal stability after the evaporation step and taking into account the amounts shown in the literature
for this growth factor when encapsulated inside PLGA NPs [24,25]. Thus, we chose 2 µg as the initial
total mass of rhBMP-2, which means a relation of 2 × 10−5% w/w (rhBMP-2/PLGA). The amount of
encapsulated rhBMP-2 was calculated by measuring the difference between the initial added amount,
and the free non-encapsulated protein present in the supernatant after the cleaning step, which was
tested by a specific enzyme-linked immuno-sorbent assay following the instructions of the manufacturer
(ELISA, kit RAB0028 from Sigma-Aldrich, St. Louis, MO, USA). Then, protein-encapsulation efficiency





where MI is the initial total mass of rhBMP-2, and MF is the total mass of rhBMP-2 in the
aqueous supernatant.
2.1.4. Physical Protein Adsorption
Bovine serum albumin (BSA) and rhBMP-2 were coupled on the empty nanoparticle surface by
a physical adsorption method. The appropriate volume of an aqueous protein solution containing
0.5 mg of BSA and 2 µg of rhBMP-2 was mixed with 5 mL of acetate buffer (pH 5) containing empty
NPs with 12.5 mg of PLGA. This provided a starting amount of proteins corresponding to 0.04% w/w
(protein/PLGA), while the mass relation between proteins was 0.4 w/w (rhBMP-2/BSA). This solution
was incubated at room temperature for 2 h under mechanical stirring. The nanoparticles were separated
from the buffer solution by centrifugation, and after the supernatants were filtered (Millipore nanofilters,
0.1 µm), they were qualitatively analyzed by gel electrophoresis while the protein quantification was
made by a bicinchoninic acid protein assay (BCA) (Sigma-Aldrich, St. Louis, MO, USA) for BSA and
the specific ELISA for rhBMP-2. The nanoparticle pellet was resuspended in phosphate buffer (pH 7.4)
and stored at 4 ◦C. This system was named NP-BSA-BMP2.
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2.1.5. Protein Separation by Gel Electrophoresis, SDS-PAGE
The protein-loaded NPs and different supernatants were treated at 90 ◦C for 10 min in the
following buffer: 62.5 mM Tris-HCl (pH 6.8 at 25 ◦C), 2% (w/v) sodium dodecyl sulfate (SDS), 10%
glycerol, 0.01% (w/v) bromophenol blue, 40 mM dithiothreitol (DTT). Samples were then separated by
size in porous 12% polyacrylamide gel (1D SDS polyacrylamide gel electrophoresis), under the effect
of an electric field. The electrophoresis was run under constant voltage (130 V, 45 min) and the gels
were stained using a Coomassie Blue solution (0.1% Coomassie Brilliant Blue R-250, 50% methanol and
10% glacial acetic acid) and destained with the same solution lacking the dye.
2.2. Nanoparticle Characterization: Morphology, Size, Concentration, and Electrokinetic Mobility
NPs were imaged by scanning electron microscopy (SEM) with a Zeiss SUPRA 40VP field-emission
scanning electron microscope from the Scientific Instrumentation Center of the University of Granada
(CIC, UGR).
The hydrodynamic size distribution of the NPs was evaluated by nanoparticle tracking analysis
(NTA) with a NanoSight LM10-HS (GB) FT14 (NanoSight, Amesbury, UK) and an sCMOS camera.
The particle concentration according to the diameter (size distribution) was calculated as an average
of at least three independent size distributions. The total concentration of NPs of each system was
determined in order to control the number of particles used in cell experiments. The measurement
conditions for all samples were 25 ◦C, a viscosity of 0.89 cP, a measurement time of 60 s, and a camera
gain of 250. The camera shutter was 11 and 15 ms for the empty and BMP-loaded NPs, respectively.
The detection threshold was fixed at 5.
The electrophoretic mobility of the NPs was determined using a Zetasizer® NanoZeta ZS device
(Malvern Instrument Ltd., Malvern, UK) working at 25 ◦C with an He-Ne laser of 633 nm, and a 173◦
scattering angle. Each data point was taken as an average over three independent sample measurements.
For each sample, the electrophoretic mobility distribution and the average electrophoretic mobility
(µ-average) were determined by the technique of laser Doppler electrophoresis.
2.3. Colloidal and Temporal Stability in Biological Media
The average hydrodynamic diameter and the polydispersity index (PDI) by dynamic light
scattering (DLS) of each NP system were measured in different media (phosphate buffer (PB) saline
phosphate buffer (PBS), and cell culture medium: Dulbecco’s modified Eagle’s medium, DMEM
(Sigma)). Also, data on temporal stability were gathered by repeating these analyses at different times
after synthesis (0, 1, and 5 days) and after 1 month under storage conditions.
In vitro release experiments were conducted as follows: 1 mL of each sample for each incubation
time was suspended in PBS at 37 ◦C. After the corresponding time (24, 48, 96, 168 h), NPs were
separated from the supernatant of released proteins by centrifugation for 10 min at 14,000 rpm (10 ◦C).
The NP pellet was suspended in 1 mL of 0.05 M NaOH and stirred for 2 h for a complete polymer
degradation. The alkaline protein solution was assayed by BCA and ELISA to quantify the unreleased
amount. The protein released was calculated taking into account the total encapsulated amount. All
experiments were made in triplicate.
2.4. Cell Interactions
For all biological in vitro studies, a cell population cultured from the maxillary alveolar bone
was used. This population was previously characterized and confirmed to present all characteristics
of a mesenchymal stromal cell population (MSC) [23]. Cells were taken from healthy human
donors after the approval from the Ethics Committee for Human Research from the University of
Granada (424/CEIH/2018). Regular Dulbecco’s modified Eagle’s medium (DMEM) with 1 g/L glucose
(DMEM-LG) (Gibco), 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA), 1:100 of
non-essential amino acid solution (NEAA) (Gibco), 0.01 µg/mL of basic fibroblast growth factor (bFGF)
Pharmaceutics 2019, 11, 388 5 of 18
(PeproTech, London, UK), 100 U/mL of penicillin/streptomycin, and 0.25 µg/mL of amphotericin B
was used as culture medium for all experiments. Cultures were maintained at 37 ◦C in a 5% CO2
atmosphere (2000 cells/well). All biological experiments were repeated in triplicate at least 3 times
per condition.
2.4.1. Cell Migration
A cell-migration assay was conducted as previously described [26,27]. Briefly, MSCs were
distributed on to three wells for each condition and allowed to grow to a cell confluency close to
99%, in 24-wells/plate at 3000 cells/cm2, and in each well three different scratches were made. Then,
cells were starved for 24 h by adding culture medium without serum. A scratch was made using
a pipette tip along the diameter of the well. A wash step with PBS was performed to remove the
scratched cells. Fresh complete culture media was added and supplemented depending on the assigned
group (BMP-2, NP- BMP2, and NP-BSA-BMP2 at 1.25, 2.5, and 5 ng/mL of BMP-2). Afterwards,
nine images were taken from the same area in each condition until 48 h later. On these images, the
scraped area was measured by ImageJ software (National Institute of Health, Bethesda, MD, USA;
http://rsbweb.nih.gov/ij/). The reduction in the scratched area over time was measured considering
the area at time 0 as 100% open.
2.4.2. Cell Proliferation
Proliferation was evaluated by a sulphorhodamine (SRB) assay [28]. The assay was conducted by
seeding the cells at 1500 cells/cm2 in a 96-well plate at a confluence not higher than 50%. After cell
attachment, the different supplements were added (BMP-2, NP- BMP2, and NP-BSA-BMP2 at 1.25,
2.5, and 5 ng/mL of BMP-2) and the cells were maintained in culture for up to 7 days. At each time
point, the cells were washed with 1X PBS and fixed by adding ice-cold 10% trichloroacetic acid for
20 min at 4 ◦C. Then, the cells were washed 3 times with dH2O and dried until all time points were
collected. Each well received 0.4% SRB in 1% acetic acid for 20 min at room temperature with gentle
shaking. The staining was finished by washing each well 3 times with 1% acetic acid and drying it at
room temperature for 24 h. The dye was retrieved from the cells by adding 10 mM Tris Base at pH 10.5
and gently shaking for 10 min. The solution recovered was then distributed in a 96-well plate and the
optical absorbance was read at 492 nm.
2.4.3. Osteogenic Differentiation
Osteogenic differentiation was evaluated by adding osteogenic media to the cell culture in
combination with free BMP-2, NP-BMP2, and NP-BSA-BMP2 at the highest dosages used in
previous experiments. Cells were seeded at 3000 cells/cm2 and cultured to reach an 85% to
90% confluency. This was followed by the addition of induction media containing 10 mM of
β-glycerophosphate (Fluka, 50020), 0.1 µM of dexamethasone (Sigma-Aldrich, D2915) and 0.05 mM
of L-ascorbic acid (Sigma-Aldrich, A8960). Cell cultures were maintained for 7 days to analyze
early activity. At day 7, cells were collected in 1 mL of TRIzol®. Then, RNA was extracted and
converted to cDNA. Alkaline phosphatase (ALP) was then evaluated, expression being calculated
relative to glyceraldehyde-3-phosphate dehydrogenase protein (GAPDH) by the 2−∆∆Ct method.
These procedures were conducted as described elsewhere [23]. Forward and reverse primer sequences
were AGCTCATTTCCTGGTATGACAAC and TTACTCCTTGGAGGCCATGTG for GAPDH, and
TCCAGGGATAAAGCAGGTCTTG and CTTTCTCTTTCTCTGGCACTAAGG for ALP.
2.4.4. Statistical Evaluation
Cell migration and proliferation were evaluated by ANOVA followed by Tukey multiple
comparisons test for pairwise analysis. Comparison between the levels of ALP at 4 vs. 7 days
were analyzed by paired Student’s t test. In all cases, a p value lower than 0.05 was established as
statistical significance.
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3. Results and Discussion
3.1. Nanoparticle Formulation
Double emulsion-solvent evaporation has been described as a robust and frequently used method
to produce biomolecule-loaded PLGA NPs [6,12,13,29]. A formulation previously optimized by
our group enabled the preservation of the biological activity of encapsulated biomolecules using a
slightly aggressive organic solvent. Moreover, deoxycholic acid has been used in the first step of the
formulation in order to improve the colloidal stability of NPs and, simultaneously, to obtain NP surfaces
enriched with carboxylic groups, improving their versatility and allowing a subsequent chemical
immobilization of different specific ligands [30]. By means of this improved formulation, in the present
work, we developed empty nanoparticles (NPs) or nanoparticles encapsulating rhBMP-2 (NP-BMP2).
A schematic description of the synthesis procedure is shown in Figure S1 of the Supplementary Data.
For NP-BMP2, we achieved a protein-encapsulation efficiency (EE) of 97 ± 2%. This result is consistent
with the literature in which several authors have reported similarly high values encapsulating this
protein inside PLGA nano- and microparticles [31,32]. Our formulation has several factors leading to
this very high EE value: The low protein/polymer relation in mass [33], the affinity of rhBMP-2 to an
unspecific interaction with hydrophobic surfaces [31], or the addition of stabilizers (poloxamer) in
the second step of the double-emulsion procedure [13]. The absence of rhBMP-2 in the supernatant
resulting from the centrifugation step in the cleaning process was verified by ELISA and SDS-PAGE, in
which a clear band corresponding to 14 kD of rhBMP-2 polypeptidic chains is shown for lane A in
Figure 1, corresponding to NP-BMP2. The mass of protein encapsulated, around 2 µg, is similar to that
of different PLGA micro- and nanosystems described in the literature [18,34,35]. Taking into account
the storage conditions for our samples, this corresponds to 500 ng/mL, which represents a sufficient
concentration for practical applications since this growth factor shows in vitro biological activities at
very low dosages (5–20 ng/mL) [13].
Pharmaceutics 2019, 11, x 6 of 18 
 
3.1. Nanoparticle Formulation 
Double emulsion-solvent evaporation has been described as a robust and frequently used 
method to produce biomolecule-loaded PLGA NPs [6,12,13,29]. A formulation previously optimized 
by our group enabled the preservation of the biological activity of encapsulated biomolecules using 
a slightly aggressive organic solvent. Moreover, deoxycholic acid has been used in the first step of 
the formulation in order to improve the colloidal stability of NPs and, simultaneously, to obtain NP 
surfaces enriched with carboxylic groups, improving their versatility and allowing a subsequent 
chemical immobilization of different specific ligands [30]. By means of this improved formulation, in 
the present work, we developed empty nanoparticles (NPs) or nanoparticles encapsulating rhBMP-2 
(NP-BMP2). A schematic description of the synthesis procedure is shown in Figure S1 of the 
Supplementary Data. For NP-BMP2, we achieved a protein-encapsulation efficiency (EE) of 97 ± 2%. 
This result is consistent with the literature in which several authors have reported similarly high 
values encapsulating this protein inside PLGA nano- and microparticles [31,32]. Our formulation has 
several factors leading to this very high EE value: The low protein/polymer relation in mass [33], the 
affinity of rhBMP-2 to an unspecific interaction with hydrophobic surfaces [31], or the addition of 
stabilizers (poloxamer) in the second step of the double-emulsion procedure [13]. The absence of 
rhBMP-2 in the supernatant resulting from the centrifugation step in the cleaning process was 
verified by ELISA and SDS-PAGE, in which a clear band corresponding to 14 kD of rhBMP-2 
polypeptidic chains is shown for lane A in Figure 1, corresponding to NP-BMP2. The mass of protein 
encapsulated, around 2 µg, is similar to that of different PLGA micro- and nanosystems described in 
the literature [18,34,35]. Taking into account the storage conditions for our samples, this corresponds 
to 500 ng/mL, which represents a sufficient concentration for practical applications since this growth 
factor shows in vitro biological activities at very low dosages (5–20 ng/mL) [13]. 
 
Figure 1. SDS polyacrylamide gel electrophoresis (SDS-PAGE) analysis under reducing conditions of 
solid PLGA Nanoparticles (PLGA NPs) and liquid (supernatant) fractions of different NP systems. 
Lane P: Protein standards; lane A: NP-BMP2 (bone morphogenetic protein); lane B: supernatant of 
NP-BMP2 after synthesis and encapsulation of rhBMP-2; lane C: NP after physical adsorption of 
BSA/rhBMP-2; lane D: supernatant after physical adsorption of BSA(bovine serum albumin)/rhBMP-
2 on NP system. 
On the other hand, a second nanosystem resulted, modifying the way in which rhBMP-2 is 
incorporated in the nanocarrier. There are several examples of surface adsorption of different growth 
factors in micro- and nanoparticles [35–37], and surface immobilization over the encapsulation has 
recently been proposed as a way to modulate the later release of biomolecules. This process, which 
Figure 1. SDS polyacrylamide gel electrophoresis (SDS-PAGE) analysis under reducing conditions of
solid PLGA Nanoparticles (PLGA NPs) and liquid (supernatant) fractions of different NP systems. Lane
P: Protein standards; lane A: NP-BMP2 (bone morphogenetic protein); lane B: supernatant of NP-BMP2
after synthesis and encapsulation of rhBMP-2; lane C: NP after physical adsorption of BSA/rhBMP-2;
lane D: supernatant after physical adsorption of BSA(bovine serum albumin)/rhBMP-2 on NP system.
On the other hand, a second nanosystem resulted, modifying the way in which rhBMP-2 is
incorporated in the nanocarrier. There are several examples of surface adsorption of different growth
factors in micro- and nanoparticles [35–37], and surface immobilization over the encapsulation has
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recently been proposed as a way to modulate the later release of biomolecules. This process, which
depends on the slow diffusion of biomolecules through the polymeric matrix, is consequently highly
influenced by the protein–polymer interaction [38,39] and polymer degradation [3,6]. Thus, this new
focus on the use of PLGA NPs for biomolecule delivery was explored by immobilizing the protein
rhBMP-2 on the surface of empty NPs by means of simple physical adsorption. This process is known
to be governed by electrostatic and hydrophobic interactions between protein molecules and NP
surfaces [40].
For this, the surface-charged groups, the hydrophilicity, the net charge of the protein molecules,
and the characteristics of the adsorption medium are the reference parameters. Thus, we designed a
co-adsorption experiment in which a mixture of rhBMP-2 and BSA (0.4% w/w, rhBMP-2/BSA) interact
simultaneously with the PLGA NP surface. Albumins are routinely used as protective proteins when
growth factors are incorporated in PLGA NPs [13,19]. Moreover, a surface distribution of BSA molecules
can improve the colloidal stability of NPs at physiological pH due to their net negative charge under
these conditions [41]. Figure S2 from Supplementary Materials shows a scheme of the co-adsorption
process. The adsorption efficiency is higher than 95% and in SDS-PAGE from Figure 1, two bands
characteristic of both proteins can be seen in lane C, corresponding to the NP-BSA-BMP2 nanosystem.
However, lane D, corresponding to the run of the supernatant from the centrifugation of the nanosystem
after adsorption processes, shows the absence of any protein. This result is fully explained by taking
into account the pH of the medium (pH 5.0), near the isoelectric point of BSA, where the adsorption of
this protein onto negatively charged nanoparticles presents a maximum [40,42]. The immobilization
of rhBMP-2 on the negatively charged surface of NPs proves they are electrostatically favored due to
the positive net charge of this protein at acid and neutral pH.
3.2. Nanoparticle Characterization
3.2.1. Nanoparticle Size
SEM and STEM micrographs (Figure 2) show that the samples consist of spherical particles of
different diameters (between 150 and 450 nm), a range similar to that found in a previous work in
which NPs were loaded with lysozyme following a similar synthesis protocol [11]. In that work,
the DLS technique failed to provide a reliable size distribution. Therefore, the NTA technique was
directly used to determine the hydrodynamic size of the BMP2-loaded NPs (see NTA video in the
Supplementary Material).
The size distributions for empty (NP) and BMP-loaded NPs (NP-BMP2) from NTA (Figure 3 and
videos S1, S2) were consistent with the SEM images. Particles with diameters between 100 and 500 nm
were found to have the highest particle concentration at around 200 nm. The loading with BMP had
an effect on the size distribution, leading to more defined peaks. These measurements enabled us
to determine the concentration of particles in the measured sample: 6.88 ± 0.09 × 108 pp/mL and
5.19 ± 0.12 × 108 pp/mL for NP and NP-BMP2 nanosystems, respectively. These values were used
(by taking into account the corresponding dilution) to control the number of particles added in the
cell experiments.
Pharmaceutics 2019, 11, 388 8 of 18
Pharmaceutics 2019, 11, x 7 of 18 
 
depends on the slow diffusion of biomolecules through the polymeric matrix, is consequently highly 
influenced by the protein–polymer interaction [38,39] and polymer degradation [3,6]. Thus, this new 
focus on the use of PLGA NPs for biomolecule delivery was explored by immobilizing the protein 
rhBMP-2 on the surface of empty NPs by means of simple physical adsorption. This process is known 
to be governed by electrostatic and hydrophobic interactions between protein molecules and NP 
surfaces [40]. 
For this, the surface-charged groups, the hydrophilicity, the net charge of the protein molecules, 
and the characteristics of the adsorption medium are the reference parameters. Thus, we designed a 
co-adsorption experiment in which a mixture of rhBMP-2 and BSA (0.4% w/w, rhBMP-2/BSA) interact 
simultaneously with the PLGA NP surface. Albumins are routinely used as protective proteins when 
growth factors are incorporated in PLGA NPs [13,19]. Moreover, a surface distribution of BSA 
molecules can improve the colloidal stability of NPs at physiological pH due to their net negative 
charge under these conditions [41]. Figure S2 from Supplementary Materials shows a scheme of the 
co-adsorption process. The adsorption efficiency is higher than 95% and in SDS-PAGE from Figure 
1, two bands characteristic of both proteins can be seen in lane C, corresponding to the NP-BSA-BMP2 
nanosystem. However, lane D, corresponding to the run of the supernatant from the centrifugation 
of the nanosystem after adsorption processes, shows the absence of any protein. This result is fully 
explained by taking into account the pH of the medium (pH 5.0), near the isoelectric point of BSA, 
where the adsorption of this protein onto negatively charged nanoparticles presents a maximum 
[40,42]. The immobilization of rhBMP-2 on the negatively charged surface of NPs proves they are 
electrostatically favored due to the positive net charge of this protein at acid and neutral pH. 
3.2. Nanoparticle Characterization 
3.2.1. Nanoparticle Size 
SEM and STEM micrographs (Figure 2) show that the samples consist of spherical particles of 
different diameters (between 150 and 450 nm), a range similar to that found in a previous work in 
which NPs were loaded with lysozyme following a similar synthesis protocol [11]. In that work, the 
DLS technique failed to provide a reliable size distribution. Therefore, the NTA technique was 
directly used to determine the hydrodynamic size of the BMP2-loaded NPs (see NTA video in the 
Supplementary Material). 
 
Figure 2. Scanning electron microscopy (SEM) micrograph of rhBMP-2-loaded nanoparticles (NP-
BMP2). 
Figure 2. Scanning electron microscopy (SEM) micrograph of rhBMP-2-loaded nanoparticles
(NP-BMP2).
Pharmaceutics 2019, 11, x 8 of 18 
 
The size distributions for empty (NP) and BMP-loaded NPs (NP-BMP2) from NTA (Figure 3 and 
videos S1, S2) were consistent with the SEM images. Particles with diameters between 100 and 500 
nm were found to have the highest particle concentration at around 200 nm. The loading with BMP 
had an effect on the size distribution, leading to more defined peaks. These measurements enabled 
us to determine the concentration of particles in the measured sample: 6.88 ± 0.09 × 108 pp/mL and 
5.19 ± 0.12 × 108 pp/mL for NP and NP-BMP2 nanosystems, respectively. These values were used (by 
taking into account the corresponding dilution) to control the number of particles added in the cell 
experiments. 
 
Figure 3. Hydrodynamic diameter distribution of NP (circles) and NP-BMP2 (thick black line) 
measured at pH 7.0 (phosphate buffer) by nanoparticle tracking analysis (NTA). 
3.2.2. Electrokinetic Mobility and Colloidal Stability 
The surface charge of nanoparticles can be analyzed using an electrokinetic study by measuring 
the electrophoretic mobility (µe) under different conditions. Figure 4 shows the µe and zeta potential 
values for the three nanosystems: NP, NP-BMP2, and NP-BSA-BMP2, at low ionic strength and 
different pH values. The electric surface charge of NPs resides in the carboxylic groups of the 
uncapped PLGA and deoxycholic acid molecules. These functionalized groups are additionally 
useful due to the possibility of a chemical surface vectorization in order to develop directed delivery 
nanocarriers [43]. It was previously confirmed that protonation of these acidic surface groups at pH 
values under their pKa value was tightly correlated with a loss of surface charge and consequently a 
reduction (in absolute value) of the electrophoretic mobility of the colloidal system [44,45]. Usually, 
when colloidal particles are coated by protein molecules, the µe values change markedly compared 
with the same bare surfaces and are influenced by the electrical charge of the adsorbed protein 
molecules [46,47]. The electrokinetic behavior of the NP-BMP2 system remains similar to that of NP, 
and encapsulation of rhBMP-2 does not affect the surface charge distribution. A similar result was 
reported by d’Angelo et al. on encapsulating different growth factors in PLGA-poloxamer blend 
nanoparticles in the same proportion w/w of protein/polymer [24]. This may be due to the low amount 
of encapsulated protein and its distribution in the inner part of the NPs (far from the surface). In our 
system, this internal distribution may be favored by the encapsulating conditions where the basic pH 
(pH 12.0) of the water phase containing rhBMP-2 allows a negative charge of these protein molecules, 
thereby preventing their electrostatic specific interaction with acidic groups of the NPs. 




























Figure 3. Hydrodynamic diameter distribution of NP (circles) and NP-BMP2 (thick black line) measured
at pH 7.0 (phosphate buffer) by nanoparticle tracking analysis (NTA).
3.2.2. Electrokinetic Mobility and Colloidal Stability
The surface charge of nanoparticles can be analyzed using an electrokinetic study by measuring
the electrophoretic mobility (µe) under different conditions. Figure 4 shows the µe an zeta potential
valu s fo the three nanos stems: NP, NP-BMP2, and NP-BSA-BMP2, at low ionic strength and
differ nt pH values. The electric surface charge of NPs resides in the carboxylic groups of the u capped
PLGA a d deoxycholic acid molecules. These functionalized groups are additionally useful due t the
possibility of a chemical surface vectorization in order to develop directed elivery n noc rriers [43].
It was previ usly c nfirmed that protonation of these acidic surface gr ups at H values und r
their pKa value was tightly correlated with a loss of surface charge and consequently a reduction (in
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absolute value) of the electrophoretic mobility of the colloidal system [44,45]. Usually, when colloidal
particles are coated by protein molecules, the µe values change markedly compared with the same
bare surfaces and are influenced by the electrical charge of the adsorbed protein molecules [46,47].
The electrokinetic behavior of the NP-BMP2 system remains similar to that of NP, and encapsulation
of rhBMP-2 does not affect the surface charge distribution. A similar result was reported by d’Angelo
et al. on encapsulating different growth factors in PLGA-poloxamer blend nanoparticles in the same
proportion w/w of protein/polymer [24]. This may be due to the low amount of encapsulated protein
and its distribution in the inner part of the NPs (far from the surface). In our system, this internal
distribution may be favored by the encapsulating conditions where the basic pH (pH 12.0) of the water
phase containing rhBMP-2 allows a negative charge of these protein molecules, thereby preventing
their electrostatic specific interaction with acidic groups of the NPs.
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Figure 4. Electrophoretic mobility and zeta potential vs. pH in buffered media of low salinity (ionic
strength equal to 0.002 M) for the different nanosystems: (black square) NP; (blue triangle) NP-BMP2;
(red circle) NP-BSA-BMP2.
The electrokinetic distribution for the NP-BSA-BMP2 system radically changes. As previously
shown, the very high adsorption efficiency leads to NPs with both proteins adsorbed around their
surface. This situation is closely correlated with the µe values from Figure 4. Taking into account the
w/w relation between adsorbed proteins (250 times higher for BSA), albumin molecules modulate the
behavior at pH values below their isoelectric point (pI 4.7), where the positive net charge of BSA masks
the original surface charge of NPs and even changes their original values to positive ones. This is a
typical result found for this protein-covering colloidal particles [42,48]. At neutral and basic pH values,
BSA molecules have a negative net charge, and the slight decrease in the absolute µe values could be
due to the reduction of the negative net surface charge of NPs, which may be shielded, at least in a
small part, by the positive charge of rhBMP-2 molecules under their basic isoelectric point (pI 9.0).
The colloidal stability for the different nanosystems (NP, NP-BMP2, and NP-BSA-BMP2) was
determined by analyzing the size distributions in various media (PB, PBS, and DMEM) at different
times after synthesis (0, 1, and 5 days). Size distributions similar to the original ones were found for
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the two formulations, NP and NP-BMP2, in all the media analyzed. This result was similar to that
previously found for these types of NPs encapsulating lysozyme [11], in which the combination of
electrostatic and steric interactions generated by surface chemical groups of NPs confer the stability
mechanism that prevents colloidal aggregation [33]. The decrease of the absolute value of the zeta
potential for the NP-BSA-BMP2 system as a consequence of surface protein distribution does not affect
its colloidal stability. This system also maintains the same size distribution in the different media. It is
commonly accepted that a zeta potential higher than +30 or −30 mV will give rise to a stable colloidal
system [49] and the zeta potential value for NP-BSA-BMP2 is above −30 mV. Colloidal stability in PBS
and DMEM, typically used media for the development of scaffold or cell interactions, respectively,
assures the potential use of these nanosystems for in vitro or in vivo living environments. Additionally,
these systems maintained their size under storage in PB, at 4 ◦C for at least 1 month (data not shown),
showing this to be an adequate medium for sample storage.
3.2.3. Protein Release
One of the main problems for micro- or nanosystems of PLGA drug delivery is to find the
appropriate release pattern for encapsulated/attached protein molecules. A wide spectrum of
formulations modulates this property by the use of different types of synthesis processes, PLGA
polymers, co-polymers, and stabilizers [3,13]. An adequate limitation and control in the burst release
is critical for BMPs in order to ensure long-term continuous release that, favored by the polymer
degradation, provides better in vivo action in driving bone and cartilage regeneration [20]. Therefore,
we previously developed a dual PLGA nanosystem for controlled short-term release, where protein
diffusion and protein–polymer interaction are the main factors governing this process [11].
In the present work, NP-BMP2 and NP-BSA-BMP2 nanosystems represent two different ways in
which rhBMP-2 was incorporated into the nanocarrier. Figure 5A shows the cumulative release of both
proteins, rhBMP-2 and BSA, for different systems as a function of time in a short-term period (7 days).
The encapsulated rhBMP-2 protein reaches an amount released of around 30% of the initial encapsulated
one while adsorbed rhBMP-2, despite its surface distribution, is three times lower. However, BSA
shows released amounts up to 80% of the initial adsorbed ones. In all cases, error bars correspond to
the standard deviations from three independent experiments. Under these conditions, the growth
factor encapsulated in NP-BMP2 presents a release pattern similar to that previously found with the
same formulation but using lysozyme as the protein [11]. Poloxamer in the water phase of the synthesis
process can be key in modulating both specific and unspecific interfacial protein interactions [50].
Thus, the relation between protein–polymer interaction and protein diffusion appears to be well
balanced, preventing an excessive initial burst and simultaneously maintaining the needed protein
flux to release around a third of the encapsulated rhBMP-2 in 7 days. Although an excessive initial
burst has been widely reported for PLGA NPs related with protein molecules close to the surface [6],
this situation did not appear for the NP-BMP2 system, this being consistent with the electrokinetic
behavior that did not show the presence of protein near surface. The literature offers some examples
with reduced short-term release of BMP-2 using more hydrophilic PLGA-PEG co-polymers [16] or a
different synthesis process [25].
The release performance for the NP-BSA-BMP2 system, also shown in Figure 5A, presents notable
differences. The electrokinetic profile has previously justified the surface location of BSA and rhBMP-2
on the surface, which could lead to a fast release of both proteins. However, results from Figure 5A,B
show this trend only for the BSA protein that is released from NPs, with about 20% of the initial amount
remaining after seven days. However, up to 90% of the initial load of rhBMP-2 protein, unlike BSA,
remains attached to the surface. The NP surface with hydrophilic groups form poloxamer molecules
and a negative charge due to the abundant presence of carboxylic groups (end-groups of PLGA and
deoxycholic acid molecules) favor a desorption process for BSA, whose molecules have a negative
charge under release conditions (physiological pH). This agrees with the results of other authors who,
even after encapsulating BSA in PLGA-poloxamer blend NPs, achieved a fast burst release of above
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40% to 50% of the initial protein amount [33]. Moreover, the co-encapsulation of albumins with growth
factors could strongly affect its release profile, causing an initial burst [21,24]. Otherwise, the specific
electrostatic attraction between positive rhBMP-2 molecules and negative surface groups slows down
the short time release of this protein. This result is in agreement with the low release of adsorbed
BMP previously found using PLGA micro- and nanoparticles with uncapped acid end groups [38,51].
Thus, the combination of different methods for trapping BMP-2 into and around NPs shows up the
possibility of attaining a properly controlled release, balancing the interactions between polymers,
stabilizers, and protein.
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Figure 5. (A) Cumulative release of rhBMP-2 for NP-BMP2 (black square) and NP-BSA-BMP2 (red
circle) systems; and cumulative release of BSA for NP-BSA-B P2 (bl e tria gle) syste , i c bated for
different ti es at 37 ◦ in saline phosphate buffer (pH 7.4). (B) SDS-PAGE analysis under reducing
conditions of solid fraction of NP-BSA-BMP2 after release at different times where the number of each
lane corresponds to the time in hours.
3.3. Biological Activity and Interactions
3.3.1. Cell Migration
Cell migration is the first and necessary step in tissue regeneration [52]. Thus, a regenerative
agent must accelerate cell migration or, at least, not interfere with it. In the present study, we found no
differences between the groups, doses, and control in terms of closure of a scratched area (ANOVA
with Tukey multiple comparisons test) (Figure 6). In contrast to our findings, previously published
data suggests a positive effect of BMP-2 on cell migration [53,54]. However, in those studies, the doses
applied, and the cell types were different than in the current experiments. We used lower doses of
BMP-2 in order to test whether, even at low dosages, BMP-2 could still provide benefits if protected
in a nanoparticle system. As mentioned, we demonstrated no negative effect of the system on cell
migration. Our results nonetheless support the idea that BMP-2 activity is mediated by the activation of
the phosphoinositide 3-kinase (PI3K) pathway, a common group of signaling molecules that participate
in several process with BMP-2 and other molecules [26,54]. It should also be mentioned that the
timeframe of a migration assay is short. Thus, the potential advantages of a controlled-release system
as the one under study might be limited. That is, the release of BMP-2 from the nanoparticles, as
demonstrated in Figure 5, is limited to the first 48 h. Thus, a sustained positive effect on migration
activity over time could be hypothesized.
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Figure 6. Migration assay. Percentage of scratched area closure at 24 and 48 h on different groups
and doses.
3.3.2. Cell Proliferation
Proliferation is another of the cell activities required for tissue regeneration. However, this property
must be balanced with both migration and differentiation, and not all three characteristics increase
at the same time and with the same ratios [55]. In fact, reportedly, when a dose of BMP-2 induces
higher proliferation, it decreases differentiation [56]. This property has been extensively analyzed but
discrepancies can still be detected in the literature. Therefore, Kim et al. analyzed different doses of
BMP-2 and its effect on cell proliferation and apoptosis. It was confirmed in vitro that high doses, but
still lower than those used clinically, reduce cell proliferation and increase apoptosis [57]. This should
be avoided. We have found that although free BMP-2 does not induce higher proliferation than the
control at any of the doses applied nor time points (ANOVA with Tukey multiple comparisons test),
the same amount of BMP-2 encapsulated or adsorbed onto PLGA nanoparticles boosts proliferation,
this being statistically significant when using a dose of 2.5 ng/mL or higher (ANOVA with Tukey
multiple comparisons test) (Figure 7). These dosages are still lower than those suggested in previous
studies. Apart from that difference, a positive effect on proliferation was still achieved. Moreover,
following the release pattern from Figure 5, more BMP-2 is expected to be released over time beyond
the 7-day time frame. Thus, a sustained induction effect could be expected as well until full confluency
of the cell culture.
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Figure 7. Proliferation of human mesenchymal stromal cells (MSCs) as measured by sulphorhodamine
(SRB) absorbance. Results were normalized to T0 in each group.
3.3.3. Osteogenic Differentiation
It has been confirmed that cell differentiation induced by BMP-2 needs the presence of permissive
osteoinductiv components. Particularly, β-glycerophosphat has been shown to exert a synergistic
effect with BMP-2 in inducing cell differentiation [56]. Thus, t test for osteogenic differentiation, we
analyzed th expression of ALP mRNA. Maximum ALP activity was fo nd t occur 10 days after
stimulation with PLGA-based microparticles c ntaining BMP-2 in co-encapsulation with human serum
alb min [16]. Although other tests could have been used to reinforce our fi dings, ALP is known to
modulate the deposition of mineralized nodules, thus indicating osteoblastic activity. For all of this, we
supplemented the differentiation media with β-glycerop osphate and either free BMP-2, NP-BMP2, or
NP-BSA-BMP2 for 4 and 7 da s s that we could capture the early dynamics of the expr ssion of the
ene. In our study, we identified an increase in the expression of LP in all groups from day 4 to day 7
(Figure 8). Alt ough ALP t day 7 in the BMP-2 group app ars to be higher than for the other two
groups, the change did not prove significant. In fact, differences between gr ps were not statistically
significant within ny time period. Noteworthy though, the increase was not significant within the
BMP-2 group (p = 0.141, Student’s t test), but it was significant within the other two groups (p = 0.025
and p = 0.003; NP-BMP2 and NP-BSA-BMP2 groups, respectively). This, again, could be taken as a
confirmation of the sustained release of the protein from the nanoparticle system beyond the earlier
time points.
This and both the migratio and proliferation studies escribed below lead us to confirm that the
system proposed can maintain a proper release of BMP-2 over time, sustaining a positive effect on cell
migration and rolifer tion with initial reduced doses of BMP-2. The fact that the excessive initial
burst is prevented is important for the application of this nan technology in bone regeneration, as
i dentistry. In this way, the negative effects of initial high doses of BMP-2 are avoided at the same
time as the molecule is protected from denaturalization inside the NP. Thus, the regenerator effects are
maintained over time.
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4. Conclusions
In this work, a delivery PLGA-nanosystem previously developed for model proteins was chosen 
as the reference system to carry and deliver the growth factor BMP-2. This NP system, with a dual 
size distribution, was developed following a double-emulsion formulation in which the process and 
the components used were optimized to reach the appropriate colloidal and biological behavior. 
Encapsulation and adsorption are two different processes to load BMP-2 in PLGA NPs. Both were 
tested to elucidate the factors controlling them and their influence in the physico-chemical and 
biological properties of nanosystems. We verified that protein–polymer specific interactions have a 
major role in the way that protein molecules are carried and delivered from NPs. In vitro experiments 
showed that BMP-2-loaded PLGA NPs are the nanocarriers with the best release profile over the 
short-term without an initial burst and with moderate and sustained release of active protein before 
the onset of polymer degradation. Therefore, the biological activity is positive with no negative 
interaction with migration or proliferation but rather the induction of cell differentiation through the 
expression of ALP. 
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Figure 8. Relative fold change in the expression of ALP mRNA (control group: BMP2 at 4 days). * =
Statistical significance of the comparison over time (p = 0.025 and p = 0.003, Student’s t test; NP-BMP2
and NP-BSA-BMP2 groups).
4. Conclusions
In this work, a delivery PLGA-nanosystem previously developed for model proteins was chosen
as the reference system to carry and deliver the growth factor BMP-2. This NP system, with a dual
size distribution, was developed following a double-emulsion formulation in which the process
and the components used were optimized to reach the appropriate colloidal and biological behavior.
Encapsulation and adsorption are two different processes to load BMP-2 in PLGA NPs. Both were tested
to elucidate the factors controlling them and their influence in the physico-chemical and biological
properties of nanosystems. We verified that protein–polymer specific interactions have a major role in
the way that protein molecules are carried and delivered from NPs. In vitro experiments showed that
BMP-2-loaded PLGA NPs are the nanocarriers with the best release profile over the short-term without
an initial burst and with moderate and sustained release of active protein before the onset of polymer
degradation. Therefore, the biological activity is positive with no negative interaction with migration
or proliferation but rather the induction of cell differentiation through the expression of ALP.
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Figure S1. Scheme of the formulati n of NP-BMP2; Figure S2: Scheme of the protein adsorption process for
NP-BSA-BMP2; Video S1. NTA experiments for NP-BMP2; Video S2. NTA experiments for empty NPs.
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